BioNTech hopes to move into cancer drugs
Losses at German pharmaceutical company BioNTech quadrupled in the second quarter compared to the previous year. Now the company is confident in a change of strategy towards new cancer treatments after a sharp drop in sales of its COVID-19 vaccine. BioNTech reported a second-quarter net loss of €807.8 million.
ENTRADAS POPULARES
UK sets new climate target for 2035
noviembre 13, 2024
Children go back to school after Valencia floods
noviembre 13, 2024
Researchers document huge decline in African elephants
noviembre 13, 2024
Mission: Impossible 8 title revealed
noviembre 13, 2024
TRANSMISIÓN EN VIVO